Attachment 6A NCI IRB approval

Department of Health & Human Services

Public Health Service
National Institutes of Health
National Cancer Institute
Bethesda, Maryland 20892

iRIS Reference Number 338357

Amendment Letter: A
IRB Number: 11CN206
Version Date: 07/11/2014

07/11/2014
TO:

Qing Lan

FROM:

Chairperson, Special Studies Institutional Review Board, NCI

SUBJECT:

Action on Clinical Research Protocol Amendment

Your amendment to protocol, “A multi-center international hospital-based case-control study of lymphoma in
Asia (AsiaLymph),” was reviewed by the National Cancer Institute Special Studies Institutional Review Board
(NCI-SSIRB) by expedited review.
The SSIRB has taken the following action:
X

Approved as written. Forwarded to the CC OPS for administrative processing.
Approved with stipulations pending re-review by SSIRB Chair. See review comments.
Deferred pending response to stipulations and re-review by a subcommittee of the Board.
See review comments.
Tabled pending response to stipulations and re-review by the full SSIRB. See review
comments.

RE: Increase the accrual level by 3,800 study subjects in addition to the currently approved 6,600 study subjects,
for a new accrual ceiling of 10,400.

PI Name: Qing Lan
Protocol Title: A multi-center international hospital-based case-control study of lymphoma in Asia (AsiaLymph)

Stipulations:

Recommendations: